Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

John D. Imig, Bruce D. Hammock

Research output: Contribution to journalArticle

363 Citations (Scopus)

Abstract

The cardiovascular effects of epoxyeicosatrienoic acids (EETs) include vasodilation, antimigratory actions on vascular smooth muscle cells and anti-inflammatory actions. These endogenous lipid mediators are broken down into diols by soluble epoxide hydrolase (sEH), and so inhibiting this enzyme would be expected to enhance the beneficial cardiovascular properties of EETs. sEH inhibitors (sEHIs) that are based on 1,3-disubstituted urea have been rapidly developed, and have been shown to be antihypertensive and anti-inflammatory, and to protect the brain, heart and kidney from damage. Although challenges for the future exist - including improving the drug-like properties of sEHIs and finding better ways to target sEHIs to specific tissues - the recent initiation of the first clinical trials of sEHIs has highlighted the therapeutic potential of these agents.

Original languageEnglish (US)
Pages (from-to)794-805
Number of pages12
JournalNature Reviews Drug Discovery
Volume8
Issue number10
DOIs
StatePublished - 2009

Fingerprint

Epoxide Hydrolases
Anti-Inflammatory Agents
Cardiovascular Diseases
Acids
Vascular Smooth Muscle
Vasodilation
Antihypertensive Agents
Smooth Muscle Myocytes
Urea
Clinical Trials
Kidney
Lipids
Brain
Enzymes
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. / Imig, John D.; Hammock, Bruce D.

In: Nature Reviews Drug Discovery, Vol. 8, No. 10, 2009, p. 794-805.

Research output: Contribution to journalArticle

Imig, John D. ; Hammock, Bruce D. / Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. In: Nature Reviews Drug Discovery. 2009 ; Vol. 8, No. 10. pp. 794-805.
@article{9aab72b7b81e4d8ca0095d6aaff9f08b,
title = "Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases",
abstract = "The cardiovascular effects of epoxyeicosatrienoic acids (EETs) include vasodilation, antimigratory actions on vascular smooth muscle cells and anti-inflammatory actions. These endogenous lipid mediators are broken down into diols by soluble epoxide hydrolase (sEH), and so inhibiting this enzyme would be expected to enhance the beneficial cardiovascular properties of EETs. sEH inhibitors (sEHIs) that are based on 1,3-disubstituted urea have been rapidly developed, and have been shown to be antihypertensive and anti-inflammatory, and to protect the brain, heart and kidney from damage. Although challenges for the future exist - including improving the drug-like properties of sEHIs and finding better ways to target sEHIs to specific tissues - the recent initiation of the first clinical trials of sEHIs has highlighted the therapeutic potential of these agents.",
author = "Imig, {John D.} and Hammock, {Bruce D.}",
year = "2009",
doi = "10.1038/nrd2875",
language = "English (US)",
volume = "8",
pages = "794--805",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

AU - Imig, John D.

AU - Hammock, Bruce D.

PY - 2009

Y1 - 2009

N2 - The cardiovascular effects of epoxyeicosatrienoic acids (EETs) include vasodilation, antimigratory actions on vascular smooth muscle cells and anti-inflammatory actions. These endogenous lipid mediators are broken down into diols by soluble epoxide hydrolase (sEH), and so inhibiting this enzyme would be expected to enhance the beneficial cardiovascular properties of EETs. sEH inhibitors (sEHIs) that are based on 1,3-disubstituted urea have been rapidly developed, and have been shown to be antihypertensive and anti-inflammatory, and to protect the brain, heart and kidney from damage. Although challenges for the future exist - including improving the drug-like properties of sEHIs and finding better ways to target sEHIs to specific tissues - the recent initiation of the first clinical trials of sEHIs has highlighted the therapeutic potential of these agents.

AB - The cardiovascular effects of epoxyeicosatrienoic acids (EETs) include vasodilation, antimigratory actions on vascular smooth muscle cells and anti-inflammatory actions. These endogenous lipid mediators are broken down into diols by soluble epoxide hydrolase (sEH), and so inhibiting this enzyme would be expected to enhance the beneficial cardiovascular properties of EETs. sEH inhibitors (sEHIs) that are based on 1,3-disubstituted urea have been rapidly developed, and have been shown to be antihypertensive and anti-inflammatory, and to protect the brain, heart and kidney from damage. Although challenges for the future exist - including improving the drug-like properties of sEHIs and finding better ways to target sEHIs to specific tissues - the recent initiation of the first clinical trials of sEHIs has highlighted the therapeutic potential of these agents.

UR - http://www.scopus.com/inward/record.url?scp=70349636047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349636047&partnerID=8YFLogxK

U2 - 10.1038/nrd2875

DO - 10.1038/nrd2875

M3 - Article

C2 - 19794443

AN - SCOPUS:70349636047

VL - 8

SP - 794

EP - 805

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 10

ER -